Edwards Lifesciences Corp (EW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 2.5B 5B 7.5B FY08: 1.2B FY09: 1.3B FY10: 1.4B FY11: 1.7B FY12: 1.9B FY13: 2B FY14: 2.3B FY15: 2.5B FY16: 3B FY17: 3.4B FY18: 3.7B FY19: 4.3B FY20: 4.4B FY21: 5.2B FY22: 4.5B FY23: 5B FY24: 5.4B FY25: 6.1B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 2B 4B 6B FY08: 818.1M FY09: 922.3M FY10: 1B FY11: 1.2B FY12: 1.4B FY13: 1.5B FY14: 1.7B FY15: 1.9B FY16: 2.2B FY17: 2.6B FY18: 2.8B FY19: 3.2B FY20: 3.3B FY21: 4B FY22: 3.7B FY23: 4B FY24: 4.3B FY25: 4.7B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

0 600M 1.2B 1.8B FY16: 751.2M FY17: 1.1B FY18: 748.2M FY19: 1.1B FY20: 897.6M FY21: 1.7B FY22: 1.5B FY23: 1.3B FY24: 1.4B FY25: 1.3B FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

0 1.5B 3B 4.5B FY08: 128.9M FY09: 229.1M FY10: 218M FY11: 236.7M FY12: 291.5M FY13: 389.1M FY14: 811.1M FY15: 494.9M FY16: 569.5M FY17: 583.6M FY18: 722.2M FY19: 1B FY20: 823.4M FY21: 1.5B FY22: 1.5B FY23: 1.4B FY24: 4.2B FY25: 1.1B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 500M 1B 1.5B FY08: 419.6M FY09: 399.1M FY10: 408.3M FY11: 489.8M FY12: 491M FY13: 516.6M FY14: 625.6M FY15: 617.2M FY16: 797.4M FY17: 875.3M FY18: 939.4M FY19: 1.1B FY20: 1.1B FY21: 1.2B FY22: 723.7M FY23: 978.4M FY24: 1.1B FY25: 1.3B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

0 600M 1.2B 1.8B FY08: 153.2M FY09: 165.3M FY10: 251.4M FY11: 308.2M FY12: 362.1M FY13: 472.7M FY14: 1B FY15: 549.7M FY16: 704.4M FY17: 1B FY18: 926.7M FY19: 1.2B FY20: 1.1B FY21: 1.7B FY22: 1.2B FY23: 895.8M FY24: 542.3M FY25: 1.6B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

0 500M 1B 1.5B FY08: 102.6M FY09: 101.3M FY10: 189.6M FY11: 231.6M FY12: 253.1M FY13: 363.7M FY14: 939.4M FY15: 447M FY16: 528.3M FY17: 832.6M FY18: 688M FY19: 928.5M FY20: 647.3M FY21: 1.4B FY22: 973.6M FY23: 642.8M FY24: 289.9M FY25: 1.3B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 250M 500M 750M FY08: 119.2M FY09: 117.5M FY10: 119.2M FY11: 119.4M FY12: 118.3M FY13: 227.6M FY14: 217M FY15: 220.3M FY16: 217.8M FY17: 215.9M FY18: 640.9M FY19: 636.7M FY20: 631.9M FY21: 631.2M FY22: 624.2M FY23: 609.4M FY24: 599.3M FY25: 585.8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 2.50 5.00 7.50 Q4 '09: 1.96 Q1 '10: 1.84 Q2 '10: 1.91 Q3 '10: 1.68 Q4 '10: 1.82 Q1 '11: 1.95 Q2 '11: 1.95 Q3 '11: 1.98 Q4 '11: 1.97 Q1 '12: 1.99 Q2 '12: 2.08 Q3 '12: 2.23 Q4 '12: 2.47 Q1 '13: 3.16 Q2 '13: 3.40 Q3 '13: 3.50 Q4 '13: 3.41 Q1 '14: 2.73 Q2 '14: 7.01 Q3 '14: 7.20 Q4 '14: 7.02 Q1 '15: 7.02 Q2 '15: 2.44 Q3 '15: 2.11 Q4 '15: 2.25 Q1 '16: 2.35 Q2 '16: 2.42 Q3 '16: 2.53 Q4 '16: 2.62 Q1 '17: 3.02 Q2 '17: 3.30 Q3 '17: 3.44 Q4 '17: 2.70 Q1 '18: 2.60 Q2 '18: 3.06 Q3 '18: 3.33 Q4 '18: 3.37 Q1 '19: 3.59 Q2 '19: 2.65 Q3 '19: 2.02 Q4 '19: 2.43 Q1 '20: 1.74 Q2 '20: 1.16 Q3 '20: 1.25 Q4 '20: 1.30 Q1 '21: 1.35 Q2 '21: 2.33 Q3 '21: 2.35 Q4 '21: 2.39 Q1 '22: 2.44 Q2 '22: 2.31 Q3 '22: 2.32 Q4 '22: 2.44 Q1 '23: 2.41 Q2 '23: 2.26 Q3 '23: 2.34 Q4 '23: 2.30 Q1 '24: 2.32 Q2 '24: 2.43 Q3 '24: 6.93 Q4 '24: 6.97 Q1 '25: 7.00 Q2 '25: 6.95 Q3 '25: 2.32 Q4 '25: 1.83 Q1 '26: 1.88 Q2 '26: 1.74 Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.